Li Mengya, Li Qian, Zhang Yinhui, Xu Changjing, Chen Zhu, Huang Yilan, Jiang Longyang
Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou, China.
School of Pharmacy, Southwest Medical University, Luzhou, China.
Sci Rep. 2025 Aug 13;15(1):29752. doi: 10.1038/s41598-025-15477-9.
In recent years, antibody-drug conjugates have become clinically significant in oncology therapeutics. Results from the POLARIX trial revealed that polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) versus rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) reported a 7.7% improvement in the 3-year progression-free survival (PFS), with no difference in overall survival (OS). This study aimed to assess the cost-effectiveness of polatuzumab vedotin in the first-line treatment of diffuse large B-cell lymphoma (DLBCL) from the perspective of the Chinese healthcare system. We constructed a 3-state partitioned survival model and a 10-year horizon to estimate the cost and utility associated with DLBCL treatment. The survival data, direct medical costs, and utilities were obtained from the POLARIX trial, YAOZHI database, and published literature. The outputs of the model include total costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs). Uncertainty was explored through one-way, probabilistic sensitivity and scenario analyses. Over a 10-year horizon, Pola-R-CHP provided an additional 0.29 QALYs versus R-CHOP, while incurring incremental costs of $31,804 and an ICER of $110,594/QALY. One-way sensitivity analysis suggested that the model was most sensitive to the utility of PFS and the cost of polatuzumab vedotin. Probabilistic sensitivity analysis showed that at the willingness-to-pay (WTP) threshold ($38,043), Pola-R-CHP was not considered cost-effective. Scenario analyses indicated that Pola-R-CHP could be a cost-effective therapeutic alternative for patients achieving long-term survival. The threshold analysis demonstrated that a 61% price reduction for polatuzumab vedotin would achieve cost-effectiveness at the WTP threshold. In the first-line treatment of DLBCL, Pola-R-CHP provides an additional health benefit over R-CHOP, but is unlikely to be cost-effective at currently published prices.
近年来,抗体药物偶联物在肿瘤治疗中已具有临床重要意义。POLARIX试验结果显示,与利妥昔单抗、环磷酰胺、多柔比星和泼尼松联合使用的泊洛妥珠单抗(Pola-R-CHP)相比,利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松(R-CHOP)的3年无进展生存期(PFS)提高了7.7%,总生存期(OS)无差异。本研究旨在从中国医疗体系的角度评估泊洛妥珠单抗一线治疗弥漫性大B细胞淋巴瘤(DLBCL)的成本效益。我们构建了一个三状态分区生存模型和一个10年的时间跨度来估计与DLBCL治疗相关的成本和效用。生存数据、直接医疗成本和效用数据来自POLARIX试验、药智数据库和已发表的文献。模型输出包括总成本、质量调整生命年(QALY)和增量成本效益比(ICER)。通过单向、概率敏感性和情景分析来探索不确定性。在10年的时间跨度内Pola-R-CHP比R-CHOP多提供0.29个QALY,同时产生31,804美元的增量成本,ICER为110,594美元/QALY。单向敏感性分析表明,该模型对PFS的效用和泊洛妥珠单抗的成本最为敏感。概率敏感性分析表明,在支付意愿(WTP)阈值(38,043美元)下,Pola-R-CHP不被认为具有成本效益。情景分析表明,对于实现长期生存的患者,Pola-R-CHP可能是一种具有成本效益的治疗选择。阈值分析表明,泊洛妥珠单抗降价61%将在WTP阈值下实现成本效益。在DLBCL的一线治疗中,Pola-R-CHP比R-CHOP提供了额外的健康益处,但按目前公布的价格不太可能具有成本效益。